<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
  <channel>
    <title>BURA Community:</title>
    <link>https://bura.brunel.ac.uk/handle/2438/8620</link>
    <description />
    <pubDate>Wed, 04 Nov 2026 14:24:23 GMT</pubDate>
    <dc:date>2026-11-04T14:24:23Z</dc:date>
    <item>
      <title>Economic and climate implications of diesel backup power in outage-affected countries</title>
      <link>https://bura.brunel.ac.uk/handle/2438/34128</link>
      <description>Title: Economic and climate implications of diesel backup power in outage-affected countries
Authors: Liu, Fangjie; Shafique, Muhammad; Liu, Yixuan; Luo, Xiaowei
Abstract: Chronic electricity outages can shift the burden of unreliable grid supply to local backup generation, yet cross-country evidence on the scale and consequences of this shift remains limited. This study develops a harmonized framework for 56 outage-affected countries that links reported outage exposure, power-system scale, and empirical seasonal demand factors to retained-demand scenarios, and evaluates the consequences of supplying the resulting backup-electricity requirement with a standardized diesel benchmark. Using source observations with their documented reference years retained (WBES outages: 2006–2024; power-system and grid-lifecycle data: 2022–2024; monthly demand: 2024; diesel-price and exchange-rate evidence: 2025), the R20 reference modeling scenario (20% retained demand) yields an expected annual backup-electricity requirement of approximately 4.275 TWh across the 56-country sample. At a reference generator efficiency of 35%, diesel fuel-cycle emissions are estimated at 3.971 MtCO2e/year, compared with 2.123 MtCO2e/year for the corresponding grid lifecycle counterfactual, yielding a net additional climate burden of 1.849 MtCO2e/year. For the 26 countries with complete matched diesel-price, grid-tariff, and exchange-rate evidence, the net avoidable operating-energy cost is USD 306.9–484.4 million/year, where the range reflects admissible tariff branches rather than probabilistic uncertainty. Country-level empirical P05–P95 ranges describe seasonal variation, while retained demand, generator efficiency, tariff evidence, and upstream diesel pathways are evaluated separately as scenario, sensitivity, and structural-robustness dimensions. The results reveal strong cross-country heterogeneity and show that aggregate burden and per-unit impact structure do not necessarily move together. The framework provides a transparent benchmark for comparing outage-driven diesel burdens and for future assessment of resilience and lower-emission backup transitions without relying on composite vulnerability scores or policy-priority thresholds.
Description: Data availability: &#xD;
Data will be made available on request.; Supplementary data are available online at: https://www.sciencedirect.com/science/article/pii/S2213138826006831#s0155 .</description>
      <pubDate>Wed, 28 Oct 2026 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">https://bura.brunel.ac.uk/handle/2438/34128</guid>
      <dc:date>2026-10-28T00:00:00Z</dc:date>
    </item>
    <item>
      <title>A Sustainable ML-Based Predictive Model for Semantically Intelligent Search Optimisation in Recruitment Systems”</title>
      <link>https://bura.brunel.ac.uk/handle/2438/34126</link>
      <description>Title: A Sustainable ML-Based Predictive Model for Semantically Intelligent Search Optimisation in Recruitment Systems”
Authors: Ajjam, Hassan; Al-Raweshidy, Hamed S
Abstract: ...
Description: Copyright ‘For the purpose of open access, the author has applied a ‘Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising.’</description>
      <pubDate>Thu, 01 Jan 2026 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">https://bura.brunel.ac.uk/handle/2438/34126</guid>
      <dc:date>2026-01-01T00:00:00Z</dc:date>
    </item>
    <item>
      <title>Recurrent mechanisms of biallelic epigenetic inactivation reveal new putative tumour suppressor genes in prostate cancer</title>
      <link>https://bura.brunel.ac.uk/handle/2438/34121</link>
      <description>Title: Recurrent mechanisms of biallelic epigenetic inactivation reveal new putative tumour suppressor genes in prostate cancer
Authors: Kiriy, Daria; Favero, Francesco; Gerhäuser, Clarissa; Heilmann, Jessica; Lutsik, Pavlo; Gonzalez, Francisco German Rodriguez; Locallo, Alessio; Jespersen, Jakob Schmidt; Gruber, Andreas J; Olsen, Andre V; Hernando, Barbara; Fu, Yunfan; Haberland, Valleriia; Furlano, Kira; Georgeson, Peter; Graefen, Markus; Phal, Pramit M; Hong, Matthew KH; Hutchison, William J; Jaratlerdsiri, Weerachai; Jiang, Jue; Schlomm, Thorsten; Cheng, Kevin CL; Mensah, Nana; Ureta, Jennifer; Keane, Thomas; Kerger, Michael; Kerry, Giselle; Kurganovs, Natalie; Pirhady, Parsa; Lach, Radoslaw; Lamb, Alastair D; Pellegrina, Diogo; Lim, Beng; Lu, Yong-Jie; Lynch, Andy G; Van Loo, Peter; Mills, Ian; Milne-Clark, Toby; Nguyen, Anne; Norden, Sam; Imada, Eddie L; Bova, G Steven; Reimand, Jüri; Nuzzo, Pier Vitale; Nykter, Matti; Macintyre, Geoff; Olofinsae, Samson; Voith von Voithenberg, Lena; Omar, Mohamed; Pakula, Hubert; Pan, Yidan; Park, Daniel J; Pederzoli, Filippo; Weischenfeldt, Joachim; Plass, Christoph; Raine, Keiran; Rodrigues, Silvia; Pereira, Ronnie Rodrigues; Xu, Yaobo; Khani, Francesca; Rubin, Alan F; Ryan, Andrew; Jung, Chol-Hee; Sankar, Aravind; Pan Prostate Cancer Group (PPCG); Schlotmann, Balthasar C; Stuchbery, Ryan; Sültmann, Holger; Brewer, Daniel S; Taylor, Avigail; Wakefield, Matthew; Warren, Anne; Wirth, Christopher; Woodcock, Dan J; Baena, Esther; Zanettini, Claudio; Zhang, Jingjing; Bristow, Robert G; Yamaguchi, Takafumi N; Ziuboniewicz, Aleksandra S; Simon, Ronald; Sauter, Guido; Batra, Rajbir RN; Kote-Jarai, Zsofia; Cooper, Colin S; Brook, Mark N; Brors, Benedikt; Butler, Adam; Cancel-Tassin, Géraldine; Costello, Tony; Corcoran, Niall M; Lamy, Philippe P; Barrowdale, Daniel; Cussenot, Olivier; Eeles, Ros A; Gihawi, Abraham; Girma, Etsehiwot G; Torres, Marina; Gnanapragasam, Vincent J; Hamid, Anis; Jakobsdottir, G Maria; Hayes, Vanessa M; He, Housheng Hansen; Hovens, Christopher M; Bedő, Justin; Leeman, Gregory; Loda, Massimo; Marchionni, Luigi; Molania, Ramyar; Grima, Corinna; Fernández-Sanromán, Angel; Dennis, Nening; Papenfuss, Anthony T; Pope, Bernard; Queiroz, Lucio R; Rausch, Tobias; Bergeron, Alain; Robinson, Brian; Sahli, Atef; Sørensen, Karina D; Uhrig, Sebastian; Wedge, David C; Dev, Harveer; Roldan-Romero, Juan Maria; Barton, Lucy; Corcoran, Niall M; Gnanapragasam, Vincent J; Mangiola, Stefano; He, Xiaotong; Hamid, Anis; He, Housheng Hansen; Hall, Grace A; Hovens, Christopher M; Dinalankara, Wikum; Kote-Jarai, Zsofia; Loda, Massimo; Molania, Ramyar; Papenfuss, Anthony T; Al-Muftah, Noora; Berlin, Alejandro; Borre, Michael; Burns, Wi; Campbell, Bethany K; Penington, Jocelyn; McCoy, Patrick; Carelli, Ryan; Cheung, Melissa; Massie, Charlie E; Chow, Ken; Clarkson, Michael J; Cmero, Marek; Collins, Colin; Holmes, Vivien; Faini, Angelo Corso; Dong, Ruining; Dundee, Philip; Foster, Chris; Erickson, Andrew; Tennstedt, Pierre; Esentürk, Emre; Hong, Chen; Peters, Justin S; Falkenbach, Fabian; Fanelli, Giuseppe N; Feran, Breon; Feuerbach, Lars; Mehmood, Arfa; Fradet, Yves
Abstract: The inactivation of tumour suppressor genes is a key step in cancer development, and is usually achieved by homozygous loss. In prostate cancer, however, large genomic regions are often hemizygously lost, which complicates the identification of putative tumour suppressors in these regions. Here, we develop Epi2Hit, an integrative computational method that leverages whole genome sequencing, epigenomic profiling and gene expression to identify biallelic inactivation of tumour suppressor genes involving DNA methylation of promoter and enhancer regions of one allele and genomic loss of the other allele. We apply Epi2Hit to a cohort of 2,021 prostate cancers to discover tumour suppressor genes. In particular, we identify epigenetic biallelic inactivation of ZFHX3 at a recurrence level similar to TP53. Biallelic inactivation of ZFHX3, a transcriptional repressor, leads to upregulation of oncogenes, including MYC and a shorter time to metastasis. Finally, we provide evidence that epigenetic silencing as 2nd hit is particularly enriched in regions with nearby essential genes, precluding homozygous loss.
Description: Data availability: &#xD;
PPCG dataset comprises whole-genome sequencing (WGS), RNA-seq, DNA methylation, clinical, and histopathological data from 2,021 prostate cancer donors. Due to the sensitive nature of human genomic/clinical data and participant-consent restrictions, PPCG data are provided under controlled access and are available only for approved research purposes. Raw genome sequencing data have been deposited in the European Genome-Phenome 1360 Archive (EGA) under the study ID EGAS00001002876 and is described in the Reporting Summary and our companion manuscript29. In addition, PPCG working project data (e.g., variant calls, pipeline outputs and intermediate analyses) and harmonised RNA-seq/methylation data are made available to approved projects through secure transfer (Globus), and clinical/histopathological data are hosted in a GDPR-compliant secure environment (REDCap); access is limited to approved PPCG researchers. Access to PPCG controlled data requires submission of a Project Concept Form, available at https://panprostate.org, and approval by the PPCG Steering Committee. Requests are submitted by emailing the completed form to PPCG@icr.ac.uk. We will respond to the data access request within 14 days. We will provide guidance on the application process; access, once granted, is provided for the duration of the approved project under the applicable data access agreement/terms. To support reproducibility without redistribution of controlled PPCG data, we provide a compact, self-contained example dataset in the project repository that is sufficient to run the Epi2Hit workflow end-to-end and reproduce representative outputs. Specifically, the repository includes a TCGA-PRAD chromosome 8 example dataset (450 K methylation β-values for chr8, a matched gene expression matrix, prostate ATAC-seq peaks, ChromHMM segmentation, and Hi-C loops), together with example mutation calls and copy-number segment inputs used for downstream biallelic analyses. These files are provided under the repository’s data/ directory and are used by analysis/TCGA_run.ipynb (and the containerised demo) to reproduce the main workflow outputs on the example dataset. The publicly available data used in this study are available in the NCBI Gene Expression Omnibus (GEO) database under accession code GSE164347 (prostate Hi-C loops): https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16434737. The publicly available data used in this study are available in the GEO database under accession code GSE188797 (tumour ATAC-seq peaks): https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE18879736. The publicly available data used in this study are available in the GEO database under accession code GSE49402 (GSM1208743, ZFHX3 ChIP-seq): https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE4940272. The publicly available data used in this study are available from the ENCODE Project database (epigenetic marks (H3K4me3, H3K27ac) and CTCF tracks derived for prostate cancer cells (PC-3, C4-2B)): https://www.encodeproject.org/110. The remaining data are available within the Article, Supplementary Information or Source Data file. Source data are provided with this paper.; Code availability: &#xD;
Code used to generate results and plots are available at https://github.com/panprostate/Epi2Hit. A static version of the code is available at https://doi.org/10.5281/ZENODO.18788787 [122. Kiriy, D. Recurrent Mechanisms of Biallelic Epigenetic Inactivation Reveal New Putative Tumour Suppressor Genes in Prostate Cancer. (Zenodo, 2026). https://doi.org/10.5281/ZENODO.18788787.].</description>
      <pubDate>Wed, 09 Sep 2026 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">https://bura.brunel.ac.uk/handle/2438/34121</guid>
      <dc:date>2026-09-09T00:00:00Z</dc:date>
    </item>
    <item>
      <title>Integrated signatures define mutational processes in prostate cancer</title>
      <link>https://bura.brunel.ac.uk/handle/2438/34120</link>
      <description>Title: Integrated signatures define mutational processes in prostate cancer
Authors: Gruber, Andreas J; Olsen, André V; Hernando, Barbara; Cheng, Kevin CL; Gerhäuser, Clarissa; Torres, Marina; Favero, Francesco; Kiriy, Daria; Fernández-Sanromán, Ángel; Roldan-Romero, Juan Maria; Barton, Lucy; Khani, Francesca; Kote-Jarai, Zsofia; Brewer, Daniel S; Yamaguchi, Takafumi N; Lamy, Philippe; Leeman, Gregory; Loda, Massimo; Pope, Bernard; Queiroz, Lucio R; Uhrig, Sebastian; Heilmann, Jessica; Xu, Yaobo; Zanettini, Claudio; Peters, Justin S; Feran, Breon; Bergeron, Alain; Rubin, Alan F; Cmero, Marek; Collins, Colin; Lamb, Alastair D; Berlin, Alejandro; Zhang, Jingjing; Ziuboniewicz, Aleksandra S; Erickson, Andrew; Ryan, Andrew; Lynch, Andy G; Massie, Charlie E; Raine, Keiran; Faini, Angelo Corso; Nguyen, Anne; Warren, Anne; Sankar, Aravind; Sahli, Atef; Grima, Corinna; Graefen, Markus; Mehmood, Arfa; Schlotmann, Balthasar C; Hong, Chen; Foster, Chris; Woodcock, Dan J; Barrowdale, Daniel; Park, Daniel J; Phal, Pramit M; Nykter, Matti; Esentürk, Emre; Baena, Esther; Carelli, Ryan; Chow, Ken; Falkenbach, Fabian; Pederzoli, Filippo; Kerry, Giselle; Wakefield, Matthew; Fanelli, Giuseppe N; Hall, Grace; Penington, Jocelyn Sietsma; Lach, Radoslaw; Dev, Harveer; Sültmann, Holger; Pakula, Hubert; Mills, Ian; Furlano, Kira; Stuchbery, Ryan; Korbel, Jan; Ureta, Jennifer; Jiang, Jue; Bedő, Justin; Feuerbach, Lars; von Voithenberg, Lena Voith; Cheung, Melissa; Simon, Ronald; Borre, Michael; Clarkson, Michael J; Wedge, David C; Batra, Rajbir N; Kerger, Michael; Scherer, Michael; Pellegrina, Diogo; Norden, Sam; Omar, Mohamed; Mensah, Nana; Sauter, Guido; Kurganovs, Natalie; Dennis, Nening; Al-Muftah, Noora; Pirhady, Parsa; Pacey, Simon; Schlomm, Thorsten; McCoy, Patrick; Georgeson, Peter; Van Loo, Peter; Dundee, Philip; Hong, Matthew KH; Olofinsae, Samson; Bova, G Steven; Nuzzo, Pier Vitale; Tennstedt, Pierre; Pereira, Ronnie Rodrigues; Dong, Ruining; Rodrigues, Silvia; Mangiola, Stefano; Keane, Thomas; Lutsik, Pavlo; Brors, Benedikt; Milne-Clark, Toby; Costello, Tony; Rausch, Tobias; Macintyre, Geoff; Haberland, Valeriia; Holmes, Vivien; Jaratlerdsiri, Weerachai; Brook, Mark N; Burns, Wi; Dinalankara, Wikum; Eeles, Ros A; Marchionni, Luigi; Hutchison, William J; He, Xiaotong; Pan, Yidan; Lu, Yong-Jie; Reimand, Jüri; Robinson, Brian; Fu, Yunfan; Fradet, Yves; Cooper, Colin S; Bristow, Robert G; Weischenfeldt, Joachim; Pan-Prostate Cancer Group (PPCG); Butler, Adam; Lim, Beng; Cancel-Tassin, Géraldine; Corcoran, Niall M; Plass, Christoph; Molania, Ramyar; Cussenot, Olivier; Gihawi, Abraham; Girma, Etsehiwot G; Sørensen, Karina D; Gnanapragasam, Vincent J; Hamid, Anis A; Campbell, Bethany K; Hayes, Vanessa M; He, Housheng Hansen; Hovens, Christopher M; Imada, Eddie L; Papenfuss, Anthony T; Wirth, Christopher; Jakobsdottir, G Maria; Jung, Chol-Hee
Abstract: Prostate cancer follows a long and heterogeneous disease course with incompletely understood aetiology¹. Here we dissect the mutational processes shaping the genomes of 959 donors from the Pan Prostate Cancer Group and assess their clinical relevance. By integrating de novo extracted single-base substitution, insertion–deletion and copy-number signatures with six novel complex structural variant signatures, we identify eight integrated mutational footprints (IMFs) that collectively explain the mutational processes in 85% of primary prostate cancer genomes. IMFs were strongly influenced by regional biases in the genome, most prevalently androgen receptor-mediated mutagenesis and replication stress. Four IMFs, present in 37% of primary tumours, were significantly associated with shorter time to metastasis. These included reactive oxygen-species-driven mutagenesis and both canonical and non-canonical homologous recombination deficiency, the latter being enriched in patients of African ancestry. Extending to the metastatic setting, we found that IMFs predicted sensitivity to androgen receptor pathway inhibitors. Taken together, our study delineates the aetiologies and mutational processes that drive the genomic and clinical heterogeneity of prostate cancer, introduces IMFs as a unifying framework, and highlights their potential to improve both risk stratification and biomarker-guided treatment selection.
Description: Data availability: &#xD;
The PPCG dataset comprises WGS, RNA-seq, DNA methylation, clinical and histopathological data from 2,021 prostate cancer donors. Owing to the sensitive nature of human genomic and clinical data and participant-consent restrictions, PPCG data are provided under controlled access and are available only for approved research purposes. Raw genome sequencing data have been deposited in the European Genome-Phenome Archive (EGA) under the study ID EGAS00001002876 and are described in the Reporting Summary and our companion paper24. Access to raw, processed and clinical data from the Hartwig Medical Foundation can be requested at https://www.hartwigmedicalfoundation.nl/en/data/data-access-request/. XML files used to construct the TCGA clinical data can be accessed through the Genomic Data Commons portal, and the procedure for requesting access to controlled genomic data is outlined online (https://gdc.cancer.gov/access-data/obtaining-access-controlled-data). Source data are provided with this paper.; Code availability: &#xD;
The source code for reproducing analyses and figures is available at GitHub (https://github.com/panprostate/mutational-signatures). A static code repository is available at Zenodo98 (https://doi.org/10.5281/ZENODO.18754193).</description>
      <pubDate>Wed, 09 Sep 2026 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">https://bura.brunel.ac.uk/handle/2438/34120</guid>
      <dc:date>2026-09-09T00:00:00Z</dc:date>
    </item>
  </channel>
</rss>

